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Summary
Background The two most common agent groups currently responsible for photo-
allergic contact dermatitis (PACD) are organic ultraviolet (UV) absorbers in sun-
screens and topical nonsteroidal anti-inflammatory drugs (NSAIDs). However,
availability of information on the photoallergenic potential of these agents is
scarce.
Objectives To obtain current information on the frequency of PACD to 19 organic
UV absorbers and five topical NSAIDs, including newer agents, in common usage
in Europe.
Methods A prospective, multicentre photopatch test study was conducted with
1031 patients attending for investigation of suspected PACD in 30 centres across
12 European countries.
Results A total of 346 PACD reactions in 200 (19Æ4%) subjects occurred. PACD
was most commonly caused by the topical NSAIDs, ketoprofen (128 subjects)
and etofenamate (59 subjects). Of the organic UV absorbers, octocrylene, benzo-
phenone-3 and butyl methoxydibenzoylmethane most frequently elicited PACD.
The ‘newer’ organic sunscreen absorbers rarely led to PACD. There appeared to
be an association between the agents ketoprofen, octocrylene and benzophenone-
3, with several subjects developing PACD to two or all three agents concomi-
tantly. Allergic contact dermatitis (ACD) was less commonly observed than PACD,
comprising 55 reactions in 47 (5%) subjects. Irritant reactions and photo-
augmentation and photoinhibition of ACD occurred infrequently.
Conclusions The European multicentre photopatch test study has provided current
information on the relative frequency of PACD to common photoallergens. Such
data will be of value when deciding on which agents to include in a future Euro-
pean ‘baseline’ photopatch test series.
Photoallergic contact dermatitis (PACD) is the delayed-type
hypersensitivity reaction which occurs when an exogenous
agent (photoallergen) is applied to the skin and subsequently
exposed to ultraviolet (UV) and ⁄or visible radiation. Histori-
cally, several agents have been identified as photoallergens,
some of which have subsequently been removed from the
European marketplace. Currently, the two most common agent
groups are organic UV absorbers used in sunscreens and topi-
cal nonsteroidal anti-inflammatory drugs (NSAIDs).1 The inci-
dence of PACD is unknown, but it is thought to be
uncommon with frequencies of 2–10% reported among
patients referred for investigation of a photoexposed-site der-
matosis.2–4 The investigation of choice for diagnosing PACD is
photopatch testing (PPT), for which a European consensus
methodology has existed for several years.5 However, in con-
trast to conventional patch testing, for which several national
and international ‘baseline’ series of allergens exist, currently
no European ‘baseline’ PPT series has been agreed on. This is
in part because limited data exist on the current most com-
mon photoallergens in Europe.
In 2007, a group of interested clinicians met in Amsterdam
under the auspices of the European Society for Photodermatol-
ogy and the European Society of Contact Dermatitis with the
aim of setting up a European multicentre photopatch test
study (EMCPPTS).
The primary objective of the study was to determine the
frequency of PACD to 19 organic UV absorbers and five topi-
cal NSAIDs in common usage in Europe among patients pre-
senting for investigation of suspected PACD using a
standardized PPT technique.
Materials and methods
Several photobiology and contact dermatitis units across Eur-
ope were invited to participate. At the initial meeting, there
was agreement that the total target number of subjects would
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be > 1000 over a 1-year period. This figure was not gener-
ated from a formal statistical sample size calculation, but based
on consensus that it would provide a clinically valuable esti-
mate of the frequency of PACD, while being practically
achievable over the timescale intended.
Due to heterogeneous legislation and its interpretation
across different European countries, some investigators had to
seek and obtain ethical approval, whereas others did not. The
latter group considered the PPT investigation as part of routine
clinical care. The inclusion criteria specified that subjects must
be aged 18 years or older and have sufficient understanding to
give written informed consent. Those included had at least
one of the following four indications for performing PPT: (i)
an exposed-site dermatitis during summer months; (ii) any
exposed-site dermatitis; (iii) history of a sunscreen reaction;
or (iv) history of a topical NSAID skin reaction.
Exclusion criteria were: (i) potent topical steroid applied to
the photopatch test site on the back in the 5 days prior to PPT;
(ii) skin disease activity on the back which was too active to
allow PPT; and (iii) subjects prescribed systemic immuno-
suppressant medication (i.e. prednisolone, methotrexate, azathi-
oprine, ciclosporin). In addition, a relative contraindication was
any patient taking photoactive medicine (e.g. thiazides, fluor-
oquinolones, NSAIDs, quinine) at the discretion of the clinician.
PPT was conducted according to the European consensus
methodology as described previously.5 In brief, the test agents
were applied to the skin of the back and removed at 24 or
48 h, depending on the set-up at each centre. One set was
then irradiated with 5 J cm)2 UVA (or less if UVA minimal
erythemal dose testing revealed objective photosensitivity6)
while the other set was covered with a UV-impermeable
material. Readings of the test site could then be made at five
different time points: preirradiation, immediately postirradia-
tion, 24 h postirradiation, 48 h postirradiation and 72 h
postirradiation or later. However, the reading made at 48 h
postirradiation was considered the key time point and sub-
sequent data analysis focused on this.3 Prior to any subject
recruitment, all participating centres were asked to send their
UVA meters via post to the coordinating centre in Dundee for
calibration. This laboratory is International Organisation for
Standardisation (ISO) 9001 registered and U.K. Accreditation
Service (UKAS) accredited. The meters were tested using a
bank of 100-W UVA lamps and calibrated using a Bentham
model DM150 spectroradiometer (Bentham Instruments Ltd,
Reading, U.K.) with calibration traceable to the U.K. National
Physical Laboratory.
The photopatch test series of 19 organic UV absorbers and
five topical NSAIDs with the concentrations used are given in
Table 1. The 24 agents were donated by Chemotechnique
Diagnostics Ltd (Vellinge, Sweden). The 19 UV absorbers are
all in common usage and among the 26 sunscreening agents
currently permitted for use in cosmetic products by the Euro-
pean Commission.7 All UV absorbers were tested at a concen-
tration of 10%, except benzophenone-4, which was used at a
2% concentration due to the irritant potential of higher
concentrations discovered during a pilot irritancy study.8 The
concentrations of the topical NSAIDs used were chosen after
consensus was reached by several members at the initiation
meeting who had expertise in testing with these agents. All
agents were prepared in petrolatum except terephthalylidene
dicamphor sulfonic acid which was prepared in water, as it
has a low pH which requires the addition of a neutralizing
agent to prevent irritant reactions.
All PPT reactions were graded using the International Con-
tact Dermatitis Research Group (ICDRG) system.9 Investigators
were asked to assign relevance to any positive reactions seen
whenever possible using the COADEX system.10 This classifies
positive reactions as follows: C, current relevance; O, old ⁄past
relevance; A, an active sensitization reaction; D, unknown rel-
evance; E, history of exposure but not resulting in dermatitis;
X, cross-reaction with another test agent. A single-sided
A4-size paper proforma was used to record anonymous data
for each subject (Appendix S1; see Supporting information).
Table 1 The European multicentre photopatch test study test agents,
with chemical abstracts service (CAS) numbers and concentrations
Test agenta CAS number
Concentration
(%)
Butyl methoxydibenzoylmethane 70356-09-1 10
Homosalate 8045-71-4 10
4-Methylbenzylidene camphor 36861-47-9 10
Benzophenone-3 131-57-7 10
Ethylhexyl methoxycinnamate 5466-77-3 10
Phenylbenzimidazole sulfonic
acid
27503-81-7 10
Benzophenone-4 4065-45-6 2
Drometrizole trisiloxane 155633-54-8 10
Octocrylene 6197-30-4 10
Ethylhexyl salicylate 118-60-5 10
Ethylhexyl triazone 88122-99-0 10
Isoamyl-p-methoxycinnamate 71617-10-2 10
Terephthalylidene dicamphor
sulfonic acid
90457-82-2 10
bis-Ethylhexyloxyphenol
methoxyphenyl triazine
187393-00-6 10
Methylene bis-benzotriazolyl
tetramethylbutylphenol
103597-45-1 10
Diethylamino hydroxybenzoyl
hexyl benzoate
302776-68-7 10
Disodium phenyl
dibenzimidazole tetrasulfonate
180898-37-7 10
Diethylhexyl butamido triazone 154702-15-5 10
Polysilicone-15 207574-74-1 10
Ketoprofen 22071-15-4 1
Etofenamate 30544-47-9 2
Piroxicam 36322-90-4 1
Diclofenac 15307-79-6 5
Ibuprofen 15687-27-1 5
Control (Pet) n ⁄a n ⁄a
aInternational Nomenclature of Cosmetic Ingredients (INCI)
name (for organic ultraviolet absorbers). Pet, petrolatum; n ⁄a,
not applicable.
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The study proforma allowed space for inclusion of up to three
of a subject’s ‘own agents’ to be tested ‘as is’, e.g. commercial
sunscreens. When completed, each proforma was faxed or
posted to the coordinating centre in Dundee. The information
included on all proformas received was entered into a secure
database for subsequent data analysis.
Results
When using the above PPT methodology and ICDRG reaction
grading system, interpretation allows six possible reaction pat-
terns to be determined, as previously described.3 These are
PACD, allergic contact dermatitis (ACD), photoaugmentation
of ACD, photoinhibition of ACD, irritant response (IR) and
negative response. In the present study, all ‘+’ ICDRG reac-
tions were discounted for the purpose of data analysis.
Baseline data
A total of 1031 subjects were recruited, of whom 715
(69Æ4%) were female. The median age of subjects was
46 years (range 18–92). Regarding photopatch application
time, this was 24 h in 679 (65Æ9%) subjects and 48 h in 347
(33Æ7%), with no duration specified in five subjects. The dose
of UVA used for irradiation was 5 J cm)2 in 977 (94Æ8%)
subjects, with the remaining 54 subjects receiving < 5 J cm)2.
Subjects were recruited from 30 centres across 12 European
countries. The number of subjects recruited by each centre is
given in Figure 1 which shows that two U.K. centres
accounted for 439 (42Æ6%) of the 1031 subjects recruited.
The recruitment period had to be extended from 12 to
32 months (August 2008 to February 2011). One factor that
contributed to the delay in subject recruitment at some centres
was the completion of paperwork required to comply with
the EU clinical trials directive.11
Photoallergic contact dermatitis reactions
A total of 346 PACD reactions in 200 subjects were recorded.
Therefore, 19Æ4% of subjects had at least one PACD reaction, a
frequency higher than in many previous studies. There was
great variation in the frequency of PACD at each centre, rang-
ing from 0% to 90Æ9% of subjects investigated (Appendix S2;
see Supporting information). The number of PACD reactions
recorded for each agent, with the corresponding ICDRG grade
of the reaction in the irradiated set is given in Table 2. Of the
346 PACD reactions, 343 were assigned COADEX relevance, as
follows: C = 152; O = 38; A = 1; D = 110; E = 3; X = 39
(Appendix S3; see Supporting information). The number of
PACD reactions to ketoprofen, etofenamate, octocrylene and
benzophenone-3 were high enough to allow analysis of PACD
rates to each agent in each country (Appendix S4; see
Supporting information). If reactions to NSAIDs were
excluded, there were 148 PACD reactions in 95 subjects to the
19 organic UV absorbers, giving a lower PACD rate of 9Æ2%.
The frequency of PACD appeared to vary with duration of
patch application. Of the 679 subjects who had patches
applied for 24 h, 94 (13Æ8%) had at least one PACD reaction,
whereas of the 347 subjects who had patches applied for
48 h, 105 (30Æ2%) had at least one PACD reaction. In the case
of gender, of the 715 women recruited, 118 (16Æ5%) had at
least one PACD reaction, compared with 82 (26Æ2%) of the
313 male subjects. The effect of age on the frequency of
PACD was analysed by grouping subjects into 10-year blocks,
as given in Table 3. After the age group 28–37 years, the fre-
quency of PACD gradually decreased with age, except among
subjects aged 78 years and older.
The frequency of PACD by diagnosis is shown in Table 4.
As regards the 54 subjects in whom a dose < 5 J cm)2 was
used for irradiation, the median dose used was 2Æ5 J cm)2
(range 0Æ25–4) and nine (16Æ7%) had at least one PACD reac-
tion. When the indication for testing was examined, subjects
who gave a history of reacting to a sunscreen or topical
NSAID had higher rates of PACD than those with an exposed-
site dermatitis or dermatitis in summer months (Table 5).
Further analysis showed that of the 139 subjects with a history
of reacting to a topical NSAID, 97 (69Æ8%) had at least one
PACD reaction to one of the five NSAID test agents compared
with 164 (15Æ9%) subjects of the total 1031 subjects
recruited.
There appeared to be an association between PACD reactions
to the three agents, ketoprofen, benzophenone-3 and octocryl-
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Fig 1. Recruitment of subjects in the
European multicentre photopatch test study by
centre (centres 1 and 2 were in the U.K.).
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ene, as given in Table 6. Further analysis of COADEX relevance
in subjects who reacted to two or all three of these agents,
showed that ketoprofen was commonly assigned current or old
relevance with octocrylene and ⁄or benzophenone-3 assigned as
cross-reactions (Appendix S5; see Supporting information).
Other reaction patterns
In comparison to PACD, ACD was much less frequent, with a
total of 55 reactions recorded in 47 (4Æ6%) subjects. Nine of
the 24 test agents did not lead to any ACD reactions. The
number of ACD reactions reported for the remaining 15
agents, with corresponding ICDRG grade of reaction are given
in Table 7. As with PACD reactions, most ACD reactions were
assigned current or unknown relevance. Photoaugmentation
and photoinhibition of ACD were relatively uncommon reac-
tion patterns, with only 21 reactions in 18 (1Æ7%) subjects
and 14 reactions in 11 (1Æ1%) subjects, respectively. Similarly,
Table 2 Photoallergic contact dermatitis (PACD) reactions to the 19
organic ultraviolet (UV) absorbers and five topical nonsteroidal anti-
inflammatory drugs in the European multicentre photopatch test study
at 48 h postirradiation, with International Contact Dermatitis Research
Group (ICDRG) grading of reactions in the irradiated set of test agents
Test agenta
Number of
subjects
with
PACD
reaction
ICDRG grade of
PACD reaction
in irradiated set
+ ++ +++
Ketoprofen 128 23 65 40
Etofenamate 59 32 24 3
Octocrylene 41 11 19 11
Benzophenone-3 37 14 18 5
Butyl methoxydibenzoylmethane 18 10 6 2
Isoamyl-p-methoxycinnamate 10 4 6 0
Ethylhexyl methoxycinnamate 7 3 3 1
Methylene bis-benzotriazolyl
tetramethylbutylphenol
5 5 0 0
Piroxicam 5 4 1 0
Terephthalylidene dicamphor
sulfonic acid
4 2 2 0
Diethylamino hydroxybenzoyl
hexyl benzoate
4 2 2 0
Ibuprofen 4 3 1 0
4-Methylbenzylidene camphor 3 1 2 0
Benzophenone-4 3 1 2 0
Ethylhexyl triazone 3 3 0 0
bis-Ethylhexyloxyphenol
methoxyphenyl triazine
3 1 1 1
Disodium phenyl
dibenzimidazole tetrasulfonate
3 2 1 0
Ethylhexyl salicylate 2 2 0 0
Diclofenac 2 1 1 0
Homosalate 1 1 0 0
Drometrizole trisiloxane 1 0 1 0
Polysilicone-15 1 1 0 0
Phenylbenzimidazole sulfonic
acid
0 0 0 0
Diethylhexyl butamido triazone 0 0 0 0
Control (Pet) 2 2 0 0
Total 346 128 155 63
aInternational Nomenclature of Cosmetic Ingredients (INCI)
name (for organic UV absorbers). Pet, petrolatum.
Table 3 Frequency of photoallergic contact dermatitis (PACD)
reactions by age group
Subject
age
(years)
Total
number
of subjects
Subjects with at least
1 PACD reaction
n %
18–27 117 20 17Æ1
28–37 191 45 23Æ6
38–47 243 53 21Æ8
48–57 205 39 19
58–67 177 25 14Æ1
68–77 80 11 13Æ8
78–87 17 6 35Æ3
88–97 1 1 100
Table 4 Frequency of photoallergic contact dermatitis (PACD)
reactions by diagnosis
Diagnosis
Total
number
of
subjects
Subjects with at
least 1 PACD
reaction
n %
Atopic dermatitis 69 9 13Æ0
CAD 31 6 19Æ4
PLE 190 25 13Æ1
Other 393 80 20Æ4
Undiagnosed 343 75 21Æ9
CAD, chronic actinic dermatitis; PLE, polymorphic light
eruption.
Table 5 Indication for testing and frequency of photoallergic contact
dermatitis (PACD)
Indication for testing
Total
number
of
subjects
Subjects with
at least 1
PACD
reaction
n %
Exposed-site dermatitis in
summer
517 83 16Æ1
Any exposed-site dermatitis 308 27 8Æ8
History of sunscreen reaction 226 63 27Æ9
History of NSAID reaction 139 97 69Æ8
NSAID, nonsteroidal anti-inflammatory drug.
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irritant reactions were rare, with only seven reactions in six
(0Æ6%) subjects observed.
Testing to ‘own’ agents
A total of 347 of 1031 subjects had at least one ‘own’ agent
tested in addition to the 24 test agents. For analysis, these
were grouped into three main categories: (i) sunscreens ‘as is’
or other UV absorbers; (ii) topical NSAIDs; and (iii) ‘other’
agents (which included systemic medications and miscella-
neous agents). A total of 48 PACD reactions in 48 (13Æ8%)
subjects were recorded 48 h postirradiation, as given in
Table 8. Eleven sunscreen reactions were assigned current rele-
vance, with 15 assigned as unknown. A total of 46 ACD reac-
tions in 40 (3Æ9%) subjects were recorded to additional ‘own’
agents 48 h postirradiation, 33 of which were to sunscreens,
13 to ‘other agents’ and zero to topical NSAIDs.
Discussion
The EMCPPTS was conducted to generate a clearer picture of
which agents currently in use in this area most frequently led
to PACD.
Ketoprofen led to PACD in the greatest number of subjects,
which suggests it may be a potent photoallergen, as has been
previously reported.12,13 The finding of likely cross-reaction in
subjects between ketoprofen and benzophenone-3 has been
previously reported, and can be explained by the benzophe-
none-like structure of ketoprofen.14 However, ketoprofen and
octocrylene PACD also appear associated, but this finding can-
not be as easily explained by close structural similarity. This
association has stimulated experimental work investigating
possible molecular mechanisms for octocrylene allergenicity.15
Although benzophenone-3 is declining in use, octocrylene use
in sunscreens is increasing over time as it is effective at stabi-
lizing butyl methoxydibenzoylmethane.16
In 2009, concerns about interactions with octocrylene led
regulatory authorities in France to suspend all marketing
authorizations for topical ketoprofen. This in turn led to a
risk–benefit analysis by the European Medicines Agency.
Although a ‘positive benefit balance’ was given, it can now be
prescribed only by clinicians, and patients are given more
warnings about the risk of developing PACD.17 The findings
of the EMCPPTS appear to confirm recent reports on the asso-
ciation between octocrylene and ketoprofen.15,18 Such findings
will be of concern to sunscreen manufacturers, whose octocry-
lene-containing sunscreens may lead to PACD in individuals
who have been previously sensitized to ketoprofen. It appears
Table 6 The association of photoallergic contact dermatitis (PACD)
reactions between ketoprofen, octocrylene and benzophenone-3 in
subjects
Agent or combination
of agents
Number of subjects
with positive PACD
reaction to agent(s)
Ketoprofen 128
Octocrylene 41
Benzophenone-3 37
Octocrylene and ketoprofen 34
Octocrylene and benzophenone-3 18
Ketoprofen and benzophenone-3 22
All three agents 15
Table 7 Allergic contact dermatitis (ACD) reactions to 15 organic
ultraviolet (UV) absorbers and topical nonsteroidal anti-inflammatory
drugs in the European multicentre photopatch test study at 48 h
postirradiation, with International Contact Dermatitis Research Group
(ICDRG) grading of reactions recorded
Test agenta
Number of
subjects
with ACD
reaction
ICDRG grade of
ACD reaction
+ ++ +++
Methylene bis-benzotriazolyl
tetramethylbutylphenol
11 8 3 0
Etofenamate 10 3 6 1
Octocrylene 7 4 3 0
Benzophenone-3 6 6 0 0
4-Methylbenzylidene
camphor
4 4 0 0
Terephthalylidene dicamphor
sulfonic acid
4 4 0 0
Butyl methoxydibenzoylmethane 3 2 1 0
Ethylhexyl methoxycinnamate 2 2 0 0
Isoamyl-p-methoxycinnamate 2 2 0 0
Ethylhexyl salicylate 1 1 0 0
bis-Ethylhexyloxyphenol
methoxyphenyl triazine
1 1 0 0
Diethylamino hydroxybenzoyl
hexyl benzoate
1 0 0 1
Disodium phenyl
dibenzimidazole tetrasulfonate
1 1 0 0
Piroxicam 1 0 1 0
Ibuprofen 1 1 0 0
Totals 55 39 14 2
aInternational Nomenclature of Cosmetic Ingredients (INCI)
name (for organic UV absorbers).
Table 8 Photoallergic contact dermatitis (PACD) reactions to additional
‘own’ agents at 48 h postirradiation with International Contact
Dermatitis Research Group (ICDRG) gradings in the irradiated set
Agent category
Total
number
of reactions
ICDRG grade of PACD
reaction in irradiated set
+ ++ +++
Sunscreen ⁄UV
absorber
30 28 2 0
NSAID 8 2 0 6
Other 10 5 5 0
UV, ultraviolet; NSAID, nonsteroidal anti-inflammatory drugs.
 2012 The Authors
BJD  2012 British Association of Dermatologists 2012 166, pp1002–1009
1006 European photopatch test study, EMCPPTS Taskforce
that ketoprofen may belong to a category of potent photoaller-
gens such as tetrachlorosalicylanilide and carprofen.19,20 In the
case of both these agents, it was only after the agent was mar-
keted that frequent episodes of photoallergy arose. The fact
that agents like ketoprofen continue to emerge onto the mar-
ketplace questions whether current preclinical screening meth-
ods for detecting PACD are adequate.
The agent leading to PACD in the second largest number of
subjects was the topical NSAID etofenamate. This anthranilic
acid derivative is not available in the U.K., but is often used
in Mediterranean countries. There are relatively few reports of
ACD and PACD to etofenamate, but these results confirm it
has photoallergenic potential.21 Most etofenamate PACD reac-
tions were of unknown relevance and interestingly some
PACD reactions to etofenamate were recorded from U.K. cen-
tres. Our observations of etofenamate reactions in Dundee led
us to hypothesize that a significant number may be due to
phototoxicity, rather than PACD (Fig. 2).
The UV absorbers most commonly leading to PACD were
octocrylene and benzophenone-3. As discussed above, many
subjects may have developed cross-reactions to ketoprofen.
However, they appear to have an inherent photoallergenic po-
tential of their own. The high rates of PACD to butyl meth-
oxydibenzoylmethane are likely to be at least partly due to its
current high levels of usage within sunscreen preparations.16
However, its role as the most important UVA absorber in sun-
screens is likely to outweigh the relatively low risk of PACD
and ACD for manufacturers.
Analysis of the four agents most commonly leading to
PACD suggests that PACD to ketoprofen, octocrylene and ben-
zophenone-3 may be most common in Italy, France, Belgium
and Spain. It is possible this is due to regional availability and
usage pattern differences, but as above, differences in subject
recruitment mean that such interpretation can only be made
cautiously.
The agent most commonly leading to ACD was methylene
bis-benzotriazolyl tetramethylbutylphenol (Tinosorb M; BASF,
Ludwigshafen, Germany). This widely used UVB + UVA
absorber is formulated as microfine nanoparticles, which
require addition of the surfactant decyl glucoside. In the pilot
irritancy study, it led to more positive reactions than all other
agents except benzophenone-4.8 A subsequent case of ACD to
methylene bis-benzotriazolyl tetramethylbutylphenol has been
reported, which attributed the problem to the decyl glucoside
within it.22
It is not possible to explain the apparent difference in fre-
quency of PACD between male and female subjects. Certain
previous studies have actually reported higher rates of ACD in
female subjects, but this was thought to reflect higher levels
of exposure to certain allergens, such as nickel in jewellery
and fragrances in cosmetics.23,24
When analysed by diagnosis, the rates of PACD appear
higher in those with chronic actinic dermatitis (CAD) than
either polymorphous light eruption or atopic dermatitis, but
small numbers make firm conclusions difficult. It is known
that patients with CAD have to use sunscreens more
frequently than other groups and have a higher tendency to
develop ACD and PACD to agents.25,26 The inclusion of 54
subjects in whom a UVA dose of < 5 J cm)2 had to be used
highlights that if PPT is performed correctly, members of
this group of photosensitive subjects can be still be
investigated.
When indications for testing were analysed, those with a
history of reacting to a sunscreen or topical NSAID had a high
frequency of PACD reactions, which confirms the importance
of PPT as an investigation in these subjects. However, the less
obvious indications of any exposed-site dermatitis or an
exposed-site dermatitis in the summer months, should not be
overlooked in patients presenting to the clinic.
Comparison of the EMCPPTS with the 2006 U.K. study by
Bryden et al.,3 which used the same methodology in a similar
patient group, highlighted two different outcomes. Firstly,
PACD rates in the EMCPPTS were much higher and, secondly,
ACD rates did not match PACD rates. These differences are
likely due to the inclusion of NSAIDs in the EMCPPTS and the
routine inclusion of an ‘as is’ sunscreen in the 2006 study.3
At that time obtaining pure forms of some test agents was not
possible so as a surrogate the investigators used a commercial
Fig 2. Close-up of etofenamate reaction at 24 h post irradiation in
irradiated set, displaying ‘+’ International Contact Dermatitis Research
Group grade reaction.
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SPF 60 sunscreen ‘as is’, which contained two such agents
(terephthalylidene dicamphor sulfonic acid and drometrizole
trisiloxane) for PPT. A large number of ACD and PACD reac-
tions to this commercial sunscreen were seen, but their rele-
vance could rarely be established.
Additionally, the 2006 study incorporated only one of the
nine ‘new’ UV absorbers used in the EMCPPTS, ethylhexyl
triazone. One of the most important findings in the present
study is that all nine of the newer, larger-molecular-weight
UV absorbers tested in pure form in the EMCPPTS led to
PACD infrequently. This makes biological sense, as these larger
molecules should penetrate less into the stratum corneum to
elicit ACD and PACD.
The low rates of photoaugmentation and photoinhibition of
ACD are in keeping with the 2006 study, but again serve to
remind clinicians of the possibility of false positive and nega-
tive reactions when conducting PPT.3,27 Irritant reactions were
also rarely seen which confirms the finding of the pilot irrit-
ancy study that most organic UV absorbers can be photopatch
tested at a concentration of 10%.8
There are some limitations to the study. The EMCPPTS was
performed in subjects attending clinicians with suspected
PACD. As a result, the frequency of PACD reported will be
higher than that occurring in the European population as a
whole. On a similar theme, the small numbers of subjects in
certain analysed subgroups (e.g. by diagnosis) means that cau-
tion must be exercised when interpreting and extrapolating
apparent patterns. The multicentre methodology of the study
meant that differences in subject selection for recruitment
occurred. Such differences will probably have largely
accounted for the variation observed in rates of PACD between
centres. Similar selection differences will also have contributed
to the apparent variation in rates of PACD seen between
subjects who had patches applied for 24 h (often from photo-
biology units) and those applied for 48 h (often from contact
dermatitis units). A further limitation is that there was no
accurate quantitative denominator data available in the form
of the number of subjects exposed to each test agent.
Therefore, for agents that led to few PACD reactions, this may
reflect limited exposure rather than a low photoallergenic
potential. Likewise, agents with many PACD reactions may
reflect high usage, rather than a high photoallergenic
potential.
In conclusion, the EMCPPTS has provided new information
on the relative frequency of PACD in this selected patient
group and the main photoallergens implicated. The study has
also reinforced the important place of PPT, when performed
according to the European consensus methodology, as an in-
vestigation in cases of possible PACD presenting to the clini-
cian. The results obtained will be of value to interested parties
in the future when deciding which agents to include in a new
and up-to-date European ‘baseline’ photopatch test series. It
also serves as a benchmark for tracking trends in PACD over
time and similar studies will need to be repeated periodically
to ensure agents included in photopatch test series continue to
be of relevance.
What’s already known about this topic?
• Organic sunscreen absorbers and topical nonsteroidal
anti-inflammatory drugs (NSAIDs) are the two agent
groups most commonly leading to photoallergic contact
dermatitis (PACD).
• The frequency of PACD to agents in these two groups
has been reported in previous multicentre studies.
• The availability to the public of agents in these two
groups changes over time, as new products emerge onto
the marketplace.
• Photopatch testing series require periodic updating and,
currently, no European ‘baseline’ photopatch test series
exists.
What does this study add?
• Updated information on the relative frequency of PACD
to 19 organic sunscreen absorbers, including newer
agents, and five topical NSAIDs currently used in Europe.
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